NeoGenomics, Inc.

NeoGenomics, Inc. reported a net loss of $108.0 million for fiscal year 2025, driven by a loss from operations of $115.9 million despite generating $727.3 million in revenue. The company's gross margin was $314.3 million, representing a 43.2% gross margin rate. Operating expenses totaled $430.2 million, including significant impairment charges of $27.8 million. Cash flow from operations was positive at $5.2 million, but the company used $12.3 million in investing activities and $200.3 million in financing activities, primarily for convertible debt repayment of $201.2 million. The net change in cash was negative $207.4 million, reducing cash and cash equivalents to $159.6 million at year-end. Total assets stood at $1.36 billion with stockholders' equity of $836.6 million.

Key Takeaways